Cerebrolysin for long-lasting disorders of consciousness after bleeding stroke
Tests cerebrolysin against a saline control in people with consciousness disorders after hemorrhagic stroke.
Key facts
- Who runs it
- Konkuk University Medical Center
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 12 people, planned
- Started
- 1 Jun 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Cerebrolysin
- Control
- Record updated
- 11 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a hemorrhagic stroke who have been in a disorder of consciousness (vegetative or minimally conscious state) for more than 4 weeks.
- Age
- 19 to 80 years (the registry also lists a maximum age of 120 years)
- Sex
- All sexes can join.
- Disease stage
- Hemorrhagic stroke confirmed by CT or MRI, with a disorder of consciousness lasting more than 4 weeks. The person is in a vegetative state or minimally conscious state (Coma Recovery Scale-revised).
- Earlier treatment
- Cannot have long-term treatment with medicines that may affect consciousness, such as antidepressants, antipsychotic drugs, nootropic drugs and vasodilators.
Main reasons for not taking part
- Epileptiform discharges confirmed on EEG
- Brain parenchymal defects
- Advanced liver, kidney, heart or lung disease
- Alcohol or drug abuse or dependence within the last 2 years
- Contraindications to cerebrolysin, or taking part in another therapeutic study
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patients with hemorrhagic stroke confirmed by CT or MRI
- Patients who have been in disorders of consciousness for more than 4 weeks after the onset of hemorrhagic stroke
- Patients in a vegetative state or minimally conscious state (Coma Recovery Scale -revised: CRS-R assessment)
- Age: 19 to 80 years of age
- Patients who have voluntarily given written informed consent to participate in the study by themselves or their legal representative
Who cannot take part
- Chronic treatment with medications that may affect consciousness, such as antidepressants, antipsychotic drugs, nootropic drugs, and vasodilators
- Alcohol or drug abuse or dependence within the last 2 years (DSM-V criteria)
- Administration of a contraindicated drug is essential for medical purposes
- Contraindications to the study drug (cerebrolysin)
- Patients with advanced liver, kidney, cardiac, or pulmonary disease
- History of serious illness within the last two years (cancer, hematologic, renal, hepatic, or coronary artery disease, psychiatric illness, diabetes, myocardial infarction, epilepsy), no evidence of secondary damage to major organs, and well-controlled diabetes or hypertension
- Significant systemic disease or unstable medical condition that may compromise compliance with the study protocol
- Patients with confirmed epileptiform discharges on EEG
- Patients with brain parenchymal defects
- Participation in another therapeutic study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 120 years old?
Where in South Korea
- Konkuk University Medical Center Research Coordinating CenterSeoul, South KoreaContact: Mi Soo Jang, Ph.D.Taking people
About the trial
What the trial wants to find out
Object: To determine the effect of cerebrolysin on prolonged disorders of consciousness caused by hemorrhagic stroke.
Read full original descriptionShow less
Participants: patients with prolonged disorders of consciousness due to severe traumatic brain injury
Intervention: 30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously or 100 ml normal saline, days 4-17, once/day, IV
Comparison: cerebrolysin group versus control group
Outcome: Coma Recovery Scale-revised, FDG-PET signal
The 2 groups in the trial
- CerebrolysinTreatment being tested
30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously
- ControlPlacebo, for comparison
100 ml normal saline, days 4-17, once/day, IV
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness in Patients With Hemorrhagic Stroke: A Pilot Study
- Plain-language title
- Cerebrolysin for long-lasting disorders of consciousness after bleeding strokeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT04427241, who can take part
- Record updated
- 11 May 2026